➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Mallinckrodt
McKesson
Colorcon
Dow

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Zofran And Dextrose In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000443 ↗ Ondansetron Treatment for Alcoholism Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 1969-12-31 The purpose of this study is to: a) evaluate the effectiveness of ondansetron (Zofran) in the treatment of alcohol dependent patients; b) investigate whether early versus late onset alcoholism predicts treatment outcome; and c) determine whether the early and late onset groups respond differently to treatment. Individuals will be "typed" into early onset and late onset alcoholism groups. Individuals will be randomly assigned to a 12-week outpatient treatment program.
NCT00006205 ↗ Alcohol Dependency Study: Combining Medication Treatment for Alcoholism Unknown status National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 2005-03-01 The purpose of this study is to learn whether ondansetron and topiramate either alone or in combination is safe and effective in the treatment of alcohol dependence. This 13 week out-patient clinical trial is randomized, double-blind, and placebo-controlled. There are post-study follow up visits 1, 2 and 3 months after the end of the study. Participants will receive ondansetron and topiramate either alone or in combination or a placebo coupled with psychotherapy.
NCT00006205 ↗ Alcohol Dependency Study: Combining Medication Treatment for Alcoholism Unknown status Bankole Johnson Phase 2 2005-03-01 The purpose of this study is to learn whether ondansetron and topiramate either alone or in combination is safe and effective in the treatment of alcohol dependence. This 13 week out-patient clinical trial is randomized, double-blind, and placebo-controlled. There are post-study follow up visits 1, 2 and 3 months after the end of the study. Participants will receive ondansetron and topiramate either alone or in combination or a placebo coupled with psychotherapy.
NCT00027079 ↗ Combined Pharmacotherapies for Alcoholism (Naltrexone/Ondansetron) Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 2001-09-01 This study will compare the effectiveness of ondansetron (Zofran) and naltrexone (ReVia) both alone and in combination in treating Early Onset Alcoholics versus Late Onset Alcoholics. All subjects will received standardized Cognitive Behavioral Therapy. Followup assessments will be completed at 1, 3, 6, and 9 months after treatment.
NCT00050167 ↗ Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer Completed Roche Pharma AG Phase 1 2002-11-01 Primary Objectives: - Determine the impact of each regimen on the disease free and overall survival of patients with operable breast cancer. - Determine the ability of docetaxel/capecitabine to downstage primary breast cancer when administered in the neoadjuvant setting when compared with weekly paclitaxel. - Determine the ability of each regimen to enhance breast conservation therapy when administered in the neoadjuvant setting. (See protocol text for additional objectives and details).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zofran And Dextrose In Plastic Container

Condition Name

Condition Name for Zofran And Dextrose In Plastic Container
Intervention Trials
Healthy 15
Nausea 9
Postoperative Nausea and Vomiting 6
Alcoholism 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zofran And Dextrose In Plastic Container
Intervention Trials
Vomiting 24
Nausea 22
Postoperative Nausea and Vomiting 15
Alcoholism 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zofran And Dextrose In Plastic Container

Trials by Country

Trials by Country for Zofran And Dextrose In Plastic Container
Location Trials
United States 85
Canada 27
Germany 10
India 9
Italy 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zofran And Dextrose In Plastic Container
Location Trials
Texas 22
New York 8
Virginia 5
Pennsylvania 4
California 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zofran And Dextrose In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Zofran And Dextrose In Plastic Container
Clinical Trial Phase Trials
Phase 4 21
Phase 3 12
Phase 2/Phase 3 2
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zofran And Dextrose In Plastic Container
Clinical Trial Phase Trials
Completed 51
Recruiting 18
Not yet recruiting 9
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zofran And Dextrose In Plastic Container

Sponsor Name

Sponsor Name for Zofran And Dextrose In Plastic Container
Sponsor Trials
M.D. Anderson Cancer Center 10
National Institute on Alcohol Abuse and Alcoholism (NIAAA) 7
Par Pharmaceutical, Inc. 7
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zofran And Dextrose In Plastic Container
Sponsor Trials
Other 104
Industry 50
NIH 13
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
Colorcon
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.